4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
SDGR - Schrödinger, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$19.00
DETAILS
HIGH:
$19.00
LOW:
$19.00
MEDIAN:
$19.00
CONSENSUS:
$19.00
DOWNSIDE:
3.60%
Stock News
Schrodinger Inc (SDGR) Stock Down 4.8% -- Now Undervalued? GF Score: 73/100
On August 14, 2026, Schrodinger Inc (SDGR) shares fell 4.8% to $17.58, continuing a trend of volatility as the stock has fluctuated between a 52-week high of $2
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement t.
Critical Review: Schrodinger (NASDAQ:SDGR) versus Weave Communications (NYSE:WEAV)
Weave Communications (NYSE: WEAV - Get Free Report) and Schrodinger (NASDAQ: SDGR - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends. Institutional and Insider Ownership 86.8% of Weave Communications
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
Anthropic is preparing what could be the largest IPO of 2026, and it's telling investors the pitch goes well beyond chatbots. According to the Wall Street Journal, "Anthropic is targeting a public debut in September or early October, people familiar with its plans said." In those same meetings, the company told some investors that it... The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It's Not Tech)
Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript
Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript
Schrodinger Q2 Earnings Call Highlights
Schrodinger NASDAQ: SDGR said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist.
Schrodinger Q2 Earnings Call Highlights
Schrodinger (NASDAQ: SDGR) said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist. Second-quarter ACV was $29.6 million, up 27% from a year earlier. ACV excluding contribution revenue was $22.6 million, an increase of 23%
Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates
Schrodinger, Inc. (SDGR) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.6 per share. This compares to a loss of $0.59 per share a year ago.
Schrödinger Reports Second Quarter 2026 Financial Results
NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Today Schrödinger announced financial results for the quarter ended June 30, 2026.
Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
NEW YORK--(BUSINESS WIRE)-- #AgenticAI--Schrödinger, Inc. announced a strategic agreement with BMS to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization.
Schrodinger: A Rare AI-Adjacent Disruptor Still Not Priced For It
Schrödinger is challenging the incumbent drug-trial method—physics-simulated molecular design that cuts the cost, time, and animal testing of building and screening thousands of candidates. The current EV is roughly accounted for by the software leg alone - the royalties business and the disruption TAM are barely priced in, if at all. Three drivers - a regulatory push away from animal testing, AI-led consumption growth, and Bunsen - open up asymmetric upside that is not required for the base case.
Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery
NEW YORK--(BUSINESS WIRE)---- $SDGR #BunsenAI--Schrödinger, Inc. today announced the launch of its early access version of Bunsen, its new agentic AI co-scientist.
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
/PRNewswire/ -- For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can
Schrödinger to Announce Second Quarter 2026 Financial Results on August 5
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform,.
Schrodinger, Inc. $SDGR Shares Purchased by Amova Asset Management Americas Inc.
Amova Asset Management Americas Inc. boosted its holdings in shares of Schrodinger, Inc. (NASDAQ: SDGR) by 13.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,190,837 shares of the company's stock after purchasing an additional 371,167 shares during the period. Amova
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on July 16, 2026, the company granted restricted stock units (RSUs) with respect to 3,691 shares of the company's common stock to four newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to.
AMD Is Up 150% This Year But Here Are 5 Overlooked Stocks Betting on What Comes Next
The Pentagon just earmarked over $74 billion for drone dominance and counter drone technologies in the FY2027 budget request, and that is only one slice of the AI arms race AMD and NVIDIA are fighting over.
A Look at Schrodinger Inc (SDGR) After 6.6% Decline -- GF Value $26.32 vs Price $16.25
On June 30, 2026, Schrodinger Inc (SDGR) shares fell 6.6% today, bringing the current price to $16.25. Over the past 52 weeks, shares have traded as high as $23
Price Targets
Schrodinger assumed with a Neutral at UBS
$19.00
(was $18.46)
UBS
UBS Starts Schrodinger (SDGR) at Neutral
$18.00
(was $18.79)
Michael Yee
·
UBS
Schrodinger initiated with a Neutral at Goldman Sachs
$19.00
(was $20.04)
Goldman Sachs
Schrodinger (SDGR) PT Raised to $28 at BMO Capital
$28.00
(was $18.91)
Gary Nachman
·
BMO Capital
Goldman Sachs Reiterates Neutral Rating on Schrodinger (SDGR)
$27.00
(was $19.60)
Chris Shibutani
·
Goldman Sachs
Schrodinger (SDGR) PT Lowered to $30 at Morgan Stanley
$30.00
(was $20.44)
Vikram Purohit
·
Morgan Stanley
Schrodinger initiated with an Outperform at Leerink
$29.00
(was $18.76)
Mani Foroohar
·
Leerink Partners
Schrodinger initiated with a Neutral at Goldman Sachs
$23.00
(was $20.54)
Chris Shibutani
·
Goldman Sachs